NASDAQ:CTSO - Cytosorbents Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.78 -0.30 (-3.30 %) (As of 12/12/2018 08:43 AM ET)Previous Close$9.08Today's Range$8.73 - $9.2052-Week Range$5.80 - $14.95Volume189,761 shsAverage Volume237,601 shsMarket Capitalization$294.68 millionP/E Ratio-27.44Dividend YieldN/ABeta0.53 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey. Receive CTSO News and Ratings via Email Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTSO Previous Symbol CUSIPN/A Webwww.cytosorbents.com Phone732-329-8885 Debt Debt-to-Equity Ratio0.49 Current Ratio7.03 Quick Ratio6.85 Price-To-Earnings Trailing P/E Ratio-27.44 Forward P/E Ratio-17.22 P/E GrowthN/A Sales & Book Value Annual Sales$15.15 million Price / Sales18.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book24.39 Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-8,460,000.00 Net Margins-70.97% Return on Equity-90.18% Return on Assets-49.20% Miscellaneous Employees84 Outstanding Shares31,650,000Market Cap$294.68 million OptionableOptionable Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions What is Cytosorbents' stock symbol? Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO." How were Cytosorbents' earnings last quarter? Cytosorbents Corp (NASDAQ:CTSO) issued its quarterly earnings results on Wednesday, November, 7th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04. The medical research company had revenue of $5.74 million for the quarter, compared to analyst estimates of $5.79 million. Cytosorbents had a negative return on equity of 90.18% and a negative net margin of 70.97%. View Cytosorbents' Earnings History. When is Cytosorbents' next earnings date? Cytosorbents is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Cytosorbents. What price target have analysts set for CTSO? 4 Wall Street analysts have issued 12-month price targets for Cytosorbents' shares. Their predictions range from $11.25 to $18.00. On average, they expect Cytosorbents' stock price to reach $14.8125 in the next twelve months. This suggests a possible upside of 68.7% from the stock's current price. View Analyst Price Targets for Cytosorbents. What is the consensus analysts' recommendation for Cytosorbents? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents. Has Cytosorbents been receiving favorable news coverage? Media headlines about CTSO stock have trended positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cytosorbents earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. Who are some of Cytosorbents' key competitors? Some companies that are related to Cytosorbents include Orthofix Medical (OFIX), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Cerus (CERS), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SI-Bone (SIBN), Inovio Pharmaceuticals (INO), Anika Therapeutics (ANIK) and Orthopediatrics (KIDS). Who are Cytosorbents' key executives? Cytosorbents' management team includes the folowing people: Dr. Phillip P. Chan, CEO, Pres & Director (Age 48)Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 63)Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 60)Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 79) Who are Cytosorbents' major shareholders? Cytosorbents' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Vanguard Group Inc. (3.88%), Skylands Capital LLC (1.46%), Allianz Asset Management GmbH (1.11%), Manatuck Hill Partners LLC (0.96%) and United Services Automobile Association (0.61%). Company insiders that own Cytosorbents stock include Al Kraus, Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents. Which major investors are selling Cytosorbents stock? CTSO stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Skylands Capital LLC, EAM Investors LLC, Vanguard Group Inc., EAM Global Investors LLC, Wells Fargo & Company MN and TIAA CREF Investment Management LLC. Company insiders that have sold Cytosorbents company stock in the last year include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents. Which major investors are buying Cytosorbents stock? CTSO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., United Services Automobile Association, Allianz Asset Management GmbH, Manatuck Hill Partners LLC, PEAK6 Investments LLC, Mycio Wealth Partners LLC, Bank of New York Mellon Corp and Pitcairn Co.. Company insiders that have bought Cytosorbents stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents. How do I buy shares of Cytosorbents? Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cytosorbents' stock price today? One share of CTSO stock can currently be purchased for approximately $8.78. How big of a company is Cytosorbents? Cytosorbents has a market capitalization of $294.68 million and generates $15.15 million in revenue each year. The medical research company earns $-8,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 84 workers across the globe. What is Cytosorbents' official website? The official website for Cytosorbents is http://www.cytosorbents.com. How can I contact Cytosorbents? Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected] MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)Community Ranking: 3.5 out of 5 ( )Outperform Votes: 327 (Vote Outperform)Underperform Votes: 135 (Vote Underperform)Total Votes: 462MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: What is a Fiduciary?